Seralutinib is under clinical development by Gossamer Bio and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Seralutinib’s likelihood of approval (LoA) and phase transition for Pulmonary Arterial Hypertension took place on 05 Dec 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Seralutinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Seralutinib is under development for the treatment of pulmonary arterial hypertension (PAH). It acts by targeting CSF1R, c-KIT, PDGF subtype a and PDGFB. The drug candidate is administered as an inhalation in the form of powder. It is administered orally as a capsule. It is developed based on PDGFR kinase technology.
Gossamer Bio overview
Gossamer Bio is a biopharmaceutical company that involves discovering, developing, and commercializing medicines for the disease areas of immunology, inflammation, and oncology. The company’s product portfolio includes GB002, for pulmonary arterial hypertension; GB5121 for adult patients with relapsed/refractory CNS lymphoma, and GB7208 for multiple sclerosis. The company is funded by ARCH Venture Partners LP, Omega Fund Management LLC, and Hillhouse Capital Group. Gossamer Bio is headquartered in San Diego, California, the US.
Quick View Seralutinib LOA Data
|Highest Development Stage|